Millennium Management LLC Has $584,000 Stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Millennium Management LLC lifted its position in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 23.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 343,814 shares of the company's stock after buying an additional 65,058 shares during the quarter. Millennium Management LLC owned about 0.84% of Vigil Neuroscience worth $584,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in VIGL. Blair William & Co. IL acquired a new stake in shares of Vigil Neuroscience in the fourth quarter valued at approximately $551,000. Renaissance Technologies LLC raised its stake in Vigil Neuroscience by 698.5% in the 4th quarter. Renaissance Technologies LLC now owns 367,300 shares of the company's stock valued at $624,000 after acquiring an additional 321,300 shares during the period. abrdn plc lifted its holdings in Vigil Neuroscience by 124.9% during the 4th quarter. abrdn plc now owns 528,472 shares of the company's stock valued at $898,000 after purchasing an additional 293,461 shares during the last quarter. 683 Capital Management LLC boosted its position in Vigil Neuroscience by 14.8% during the fourth quarter. 683 Capital Management LLC now owns 1,400,000 shares of the company's stock worth $2,380,000 after purchasing an additional 180,420 shares during the period. Finally, Boothbay Fund Management LLC acquired a new position in shares of Vigil Neuroscience in the fourth quarter valued at $249,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Vigil Neuroscience Stock Up 0.1%

Shares of VIGL stock traded up $0.01 during trading hours on Thursday, reaching $7.87. The company's stock had a trading volume of 3,583,095 shares, compared to its average volume of 703,991. Vigil Neuroscience, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $7.95. The firm's 50 day simple moving average is $3.78 and its 200-day simple moving average is $2.71. The company has a market capitalization of $367.31 million, a price-to-earnings ratio of -3.82 and a beta of 3.43.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.04. Sell-side analysts predict that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on VIGL. Citigroup downgraded shares of Vigil Neuroscience to a "market perform" rating in a report on Thursday, May 22nd. Guggenheim set a $8.00 target price on Vigil Neuroscience and gave the company a "neutral" rating in a research report on Thursday, May 22nd. Mizuho lowered Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Citizens Jmp cut Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, HC Wainwright lowered Vigil Neuroscience from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $14.00 to $8.00 in a report on Tuesday, May 27th. Ten research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Vigil Neuroscience presently has a consensus rating of "Hold" and a consensus price target of $10.80.

Vigil Neuroscience Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.